The rally didn't last.
More news coming out yesterday after hours that could help the cause.
XOMA Announces $6 Million Antibody Discovery Collaboration
Monday 09/14/2009 5:15 PM ET - Investrend
Symbol Last %Chg
CEPH 58.78 0.00%
XOMA 0.87 0.00%
As of 12:00 AM ET 9/14/09
(Comment on this article at http://www.financialwire.net/2009/09...llaboration-2/
September 14, 2009 (FinancialWire) -- XOMA Ltd. (NASDAQ: XOMA) and Arana Therapeutics Ltd., a wholly-owned subsidiary of Cephalon, Inc. (NASDAQ: CEPH), have entered into a collaboration involving multiple proprietary XOMA antibody research and development technologies, including a new antibody phage display library, and a suite of integrated information and data management systems.
Arana has agreed to pay XOMA a fee of $6 million and XOMA will be entitled to milestone payments and royalties on product sales. Under the terms of the collaboration, XOMA will be fully reimbursed for all services it may provide to Arana under the agreement.
XOMA has developed integrated capabilities in antibody discovery, engineering and manufacturing, including maintaining the largest collection of commercially available antibody phage display libraries. The company also has expertise in the construction of large, novel and diverse libraries for screening and optimization that enable the selection of antibodies with very specific binding, affinity and potency characteristics to an antigen of choice.
The new, proprietary antibody library covered by the agreement with Arana, recently validated by XOMA, is one of a series of proprietary antibody libraries being developed by XOMA scientists to overcome existing limitations in library design by combining "best-in-class" techniques with XOMA's own proprietary and patent-protected technologies. Access to multiple libraries may offer a number of benefits to XOMA and its partners because it enables the use of libraries best suited to the needs of a particular discovery project. This increases the probability of technical and business success in finding rare and unique functional antibodies directed to targets of interest.
FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php
). Contact FinancialWire(tm) directly via firstname.lastname@example.org
Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279